Select committee: Health and Social Care Committee
Future Cancer: NICE medicines appraisal (Enhertu)
Closed
Opened 30 Apr 2024
Closed 30 May 2024
Health and Social Care Committee Inquiry on parliament.uk ↗
Inquiry scope (the committee's words)
The committee will consider the impact of changes made by NICE to evaluate drugs used to treat patients with terminal illness like cancer in this session. The Future Cancer inquiry received evidence from drugs’ companies that changes by NICE in 2022 on the cost-effectiveness of drugs for severe diseases do not sufficiently weight treatments used in advanced cancer. They say that as a result some cancer patients may miss out on last resort treatments. MPs will also consider the breast cancer drug Enhertu which in draft guidance from NICE has not been recommended for treating secondary breast cancer in England. The APPG on Breast Cancer will hold a roundtable event focusing on this issue later the same day.
Where it stands
The inquiry is closed, opened 30 April 2024.
The committee has not published a report yet.
Evidence
- 1 oral evidence sessionLatest 8 May 2024
- 5 witnesses
Recent activity
- NICE on Enhertu and the next steps 14.04.2422 May 2024, Correspondence
- Daiichi Sankyo UK & AstraZeneca on HER2-low metastatic breast cancer NICE decision 23.04.249 May 2024, Correspondence
- Oral evidence session8 May 2024, Oral evidence
Oral evidence sessions
On smaller screens, scroll horizontally to read every column. Keyboard users can focus the table region and use the arrow keys.
| Date | Session and witnesses | Source |
|---|---|---|
| 8 May 2024 |
Oral evidence session
Baroness Delyth Morgan · Breast Cancer Now,
David Brocklehurst · AstraZeneca UK,
Dr Sam Roberts · National Institute for Health and Care Excellence (NICE),
Haran Maheson · Daiichi Sankyo UK,
Helen Knight · National Institute for Health and Care Excellence (NICE)
|
View ↗ |
Who gave evidence
On smaller screens, scroll horizontally to read every column. Keyboard users can focus the table region and use the arrow keys.
| Witness | Organisation | Sessions |
|---|---|---|
| Baroness Delyth Morgan · Chief Executive | Breast Cancer Now | 1 |
| David Brocklehurst · Head of Oncology | AstraZeneca UK | 1 |
| Dr Sam Roberts · Chief Executive | National Institute for Health and Care Excellence (NICE) | 1 |
| Haran Maheson · Vice President, Oncology | Daiichi Sankyo UK | 1 |
| Helen Knight · Director of Medicines Evaluation | National Institute for Health and Care Excellence (NICE) | 1 |
Correspondence
On smaller screens, scroll horizontally to read every column. Keyboard users can focus the table region and use the arrow keys.
| Published | Direction | Letter |
|---|---|---|
| 22 May 2024 | Not recorded | NICE on Enhertu and the next steps 14.04.24 |
| 9 May 2024 | Not recorded | Daiichi Sankyo UK & AstraZeneca on HER2-low metastatic breast cancer NICE decision 23.04.24 |